FDA Approves Dasatinib for Pediatric Philadelphia Chromosome-positive CML

Share this content:
The FDA based its approval on results from 2 ongoing clinical studies: the open-label, prospective CA180-226 phase 2 trial, and the dose-ranging CA180-018 phase 1 trial.
The FDA based its approval on results from 2 ongoing clinical studies: the open-label, prospective CA180-226 phase 2 trial, and the dose-ranging CA180-018 phase 1 trial.

The US Food and Drug Administration (FDA) has approved dasatinib for pediatric patients with chronic phase (CP) Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML), according to a press release.1

The FDA based its approval on results from 2 ongoing clinical studies: the open-label, prospective CA180-226 (ClinicalTrials.gov Identifier: NCT00777036) phase 2 trial, and the dose-ranging CA180-018 (ClinicalTrials.gov Identifier: NCT00306202) phase 1 trial.

Ninety-seven pediatric patients with CP CML treated with dasatinib were evaluated from both trials; 51 patients from the phase 2 study had newly diagnosed disease, and 46 patients in total from both studies had disease resistant or intolerant (R/I) to imatinib.

Results showed that 96.1% (95% CI, 86.5%-99.5%) and 82.6% (95% CI, 68.6%-92.2%) of patients with newly diagnosed disease and patients with R/I disease, respectively, had a complete cytogenic response (CCyR).

The median durations of CCyR, major molecular response (MMR), and major cytogenic response (MCyR) could not be evaluated at the median follow-up time of 4.5 years for newly diagnosed patients and were 5.2 years for patients with R/I disease. More than half of the patients who had a response did not have progressive disease at the time of data cut-off.

The most frequently reported adverse events occurring in more than 10% of patients were nausea, vomiting, diarrhea, abdominal pain, skin rash, headache, fatigue, arthralgia, and extremity pain.

Reference

  1. FDA approves dasatinib for pediatric patients with CML [news release]. Silver Springs, MD: US Food and Drug Administration; November 9, 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584725.htm?utm_campaign=Oncology%2011%2F13&utm_medium=email&utm_source=Eloqua&elqTrackId=e3fc8b51cc174a8eaf2296d2df9e04e1&elq=66a053c4a4fc440fac81f37231ac87d7&elqaid=1301&elqat=1&elqCampaignId=784. Accessed November 13, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters